Regenerative Medicines for Huntingtons Disease - A Pipeline Analysis Report

Overview of the drug development pipeline for regenerative medicine for Huntington’s disease

Huntington’s disease is an inherited genetic disorder that results in the death of brain cells and is fatal in nature. The risk of individuals acquiring the Huntington’s disease is 50%, with 10% of the incidence of the disease being consequent of the genetic mutation of the huntingtin gene. Individuals witness the symptoms of this disease between the age of 30-50 years, that worsen over time. This disease may also be consequent in severe complications such as pneumonia, heart failure, and others that may be terminal. Technavio’s market research analysts have predicted that with the study to repair the mutated gene with a normal healthy huntingtin gene, the extensive research on stem cell therapy and gene therapy will grow as significant therapeutic approaches the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that few drug molecules are in the discovery drug development stage in the pipeline for Huntington’s disease.

 Get A Free Sample

Drug development for regenerative medicine market report: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in drug development molecules for the treatment of regenerative medicine for Huntington’s disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.  

Some of the companies covered in this pipeline analysis report are:

• BRAINVECTIS
• SANGAMO THERAPEUTICS
• VOYAGER THERAPEUTICS

Therapeutic assessment of the drug development pipeline for regenerative medicine for Huntington’s disease by route of administration

• Intravenous
• Intrastriatal
• Intracerebral

The intravenous route of administration (ROA) involves the administration of drug substances through the various veins in the body. It has been observed that the majority of total therapeutics for Huntington’s disease are being developed for intravenous administration.

Therapeutic assessment of the drug development pipeline for regenerative medicine for Huntington’s disease by therapeutic modality

• Gene therapy
• Stem cell

According to this pipeline analysis report, the drug development pipeline for Huntington’s disease are witnessing the emergence of several gene therapies to inhibit the growth of the mutant gene and repair the mutated gene. The mutated genes could result in the permanent damage of the DNA sequence, resulting in various neurodegenerative disorders.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Technavio also offers customization on reports based on specific client requirement.